Open access · OA
via Europe PMC
Epigenetic and mitochondrial regulation in kidney disease: emerging mechanisms and therapeutic opportunities.
Rawat A, Prasad N, Komalkumar C, Singh H, Chaturvedi S, Ahmed S, Kumar B, Kushwaha RS.
Frontiers in immunology · 2026
Genomic instability
Epigenetic alterations
Deregulated nutrient-sensing
Mitochondrial dysfunction
Altered intercellular communication
Chronic inflammation
Review
Abstract
Renal fibrosis is an important pathogenic characteristic in the course of chronic kidney disease, driven by intricate interactions between mitochondrial failure and epigenetic control. The kidney is highly energy dependent and hence particularly vulnerable to mitochondrial disturbances such as decreased oxidative phosphorylation, mitochondrial reactive oxygen species (ROS) overproduction, reduced ATP production and mitochondrial DNA damage. Such changes induce oxidative stress and inflammatory reactions leading to tubular damage and fibrotic remodeling. Epigenetic processes such as DNA methylation, histone modifications and non-coding RNAs influence gene-expression programmes linked to inflammation, death, epithelial plasticity and extracellular-matrix deposition. Indeed, recent research indicates that there is reciprocal crosstalk between mitochondrial metabolism and epigenetic regulation, with metabolites such as NAD+, acetyl-CoA, α-ketoglutarate, succinate, fumarate and lactate, as well as ROS signaling, as mediators of this crosstalk. This interaction may also enhance inflammatory and fibrotic systems that drive chronic kidney disease progression. This mito-epigenetic axis has emerged as a therapeutic target. Potential strategies to mitigate renal fibrosis include SIRT1/PGC-1α signaling, AMPK activation, NRF2 antioxidant responses, epigenetic regulators (e.g., HDACs and DNMTs), and mitochondria-targeted antioxidants. Hence, this review analyses evidence according to illness, renal cell type, immunological state and translational maturity rather than considering mitochondrial and epigenetic alterations as uniform whole-kidney processes.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3389/fimmu.2026.1910925
- Canonical
- link ↗
- Fetched
- 2026-10-30 MST
Cite this
APA
A, R., N, P., C, K., H, S., S, C., S, A., B, K., & RS., K. (2026). Epigenetic and mitochondrial regulation in kidney disease: emerging mechanisms and therapeutic opportunities. <em>Frontiers in immunology</em>. https://doi.org/10.3389/fimmu.2026.1910925
Vancouver
A R, N P, C K, H S, S C, S A, et al. Epigenetic and mitochondrial regulation in kidney disease: emerging mechanisms and therapeutic opportunities. Frontiers in immunology. 2026. doi:10.3389/fimmu.2026.1910925.
BibTeX
@article{rawat2026Epigen,
title = {Epigenetic and mitochondrial regulation in kidney disease: emerging mechanisms and therapeutic opportunities.},
author = {Rawat A and Prasad N and Komalkumar C and Singh H and Chaturvedi S and Ahmed S and Kumar B and Kushwaha RS.},
journal = {Frontiers in immunology},
year = {2026},
doi = {10.3389/fimmu.2026.1910925},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in immunology
Open access · OA
Epigenetic and mitochondrial regulation in kidney disease: emerging mechanisms and therapeutic opportunities
Cells 2025
Open access · CC-BY
Mitochondrial Dysfunction: The Silent Catalyst of Kidney Disease Progression
Kidney International Reports 2021
Open access · CC-BY
Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2
World Journal of Gastroenterology 2014
Open access · CC-BY
Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease
International Journal of Molecular Sciences 2020
Open access · CC-BY
The Epigenetic Landscape of Vascular Calcification: An Integrative Perspective
Journal of Allergy and Clinical Immunology 2020
Open access · OA